Liminatus Pharma, Inc. (LIMN) Form 8-K — Nov 3, 2026
Liminatus Pharma entered into a subscription agreement on November 2, 2026 with a non-U.S. investor to sell 260,001 shares of common stock at $2.50 per share in a private placement, for aggregate gross proceeds of $650,002.50. Proceeds are earmarked for working capital and general corporate purposes. The offering is exempt from registration under Section 4(a)(2), Regulation D and/or Regulation S, and is expected to close on or about November 20, 2026.
Key figures
- Gross Proceeds
- 650002.5
- Offering Price
- 2.5
- Shares Offered
- 260001
- Closing Date
- on or about November 20, 2026
- Outside Date
- December 31, 2026
- Resale Registration Deadline
- within 60 days of closing
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.